With market exclusivity for regular Eylea ending, the company has positioned its high-dose version, marketed with Bayer ...
Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...
Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.
Hosted on MSN20d
Regeneron to Report Q3 Earnings: What's in the Offing?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...
Looking at options history for Regeneron Pharmaceuticals REGN we detected 8 trades. If we consider the specifics of each ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...
Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...
https://www.tipranks.com/news/company-announcements/ceribell-inc-reports-strong-q3-2024-growth Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback